All In Biotech

Drug Trial Radar · NCT02474420

Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients

The Use of the Calcium Channel Blocker Amlodipine as an Adjuvant Treatment to Iron Chelation for the Prevention of Iron Overload Cardiomyopathy in Patients With Thalassemia

Last checked: Nov 19, 2026Latest source record: Oct 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 2015

Primary completion

Jun 2017

Study completion Jun 2018

Sponsor

Lead sponsor
Kevin H.M. Kuo, MD, MSc, FRCPCAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open label, two arms superiority trial of a representative population of patients with a primary diagnosis of transfusion dependent thalassemia with evidence of moderate cardiac iron overload, defined as an average T2\* MRI parameter at the mid inter-ventricular septum between 10 and 20ms.

Conditions

  • Beta-Thalassemia
  • Iron Overload

Interventions

  • AmlodipineDrug

    amlodipine titrated up to 10 mg daily or maximum tolerated dose, whichever comes first

  • DeferasiroxDrug

    Deferasirox administered per standard of care by the treating physician

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in cardiac T2*Time frame: 12 months following randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Health Network

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.